1.Prevalence and Clinical Characteristics of Noncardiac Chest Pain with Reflux Esophagitis in Korea.
Ji Young MOK ; Sohyun KWON ; Kiwon SHIN ; Seonwoo OH ; Soojeong HAN ; Sang Hoon EUM ; Hee Jun KANG ; Bong Han KONG ; Byung Hee HWANG ; Jung Hwan OH
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2016;16(2):88-91
BACKGROUND/AIMS: Noncardiac chest pain (NCCP) is substernal, squeezing chest pain, unrelated to the cardiac problem. Our study aimed to define the prevalence and clinical characteristics of reflux esophagitis in NCCP patients in Korea. MATERIALS AND METHODS: We reviewed medical records of patients who visited Department of Cardiology, St. Paul's Hospital due to chest pain and had normal coronary arteriography and who had received endoscopy within 6 months. Patients diagnosed with peptic ulcer or gastric cancer were excluded. The patients were classified into two groups according to their endoscopic results; the reflux esophagitis group and the control group. RESULTS: Two hundred seventeen NCCP patients were enrolled and 96 patients (44.2%) were diagnosed with reflux esophagitis: 68 patients (31.3%) with minimal change esophagitis; 26 patients (12.0%) with Los Angeles (LA) grade A; 2 patients (0.9%) with LA grade B. There were no patients with severe erosive reflux disease. There were no significantly different characteristics in the reflux esophagitis group and the control group. CONCLUSIONS: The prevalence of reflux esophagitis in NCCP patients in Korea was 44.2%. Most patients had mild reflux esophagitis.
Angiography
;
Cardiology
;
Chest Pain*
;
Endoscopy
;
Esophagitis
;
Esophagitis, Peptic*
;
Gastroesophageal Reflux
;
Humans
;
Korea*
;
Medical Records
;
Peptic Ulcer
;
Prevalence*
;
Stomach Neoplasms
;
Thorax*
2.Improved Gait Speed After Robot-Assisted Gait Training in Patients With Motor Incomplete Spinal Cord Injury: A Preliminary Study.
Seungwon HWANG ; Hye Ri KIM ; Zee A HAN ; Bum Suk LEE ; Soojeong KIM ; Hyunsoo SHIN ; Jae Gun MOON ; Sung Phil YANG ; Mun Hee LIM ; Duk Youn CHO ; Hayeon KIM ; Hye Jin LEE
Annals of Rehabilitation Medicine 2017;41(1):34-41
OBJECTIVE: To evaluate the clinical features that could serve as predictive factors for improvement in gait speed after robotic treatment. METHODS: A total of 29 patients with motor incomplete spinal cord injury received 4-week robot-assisted gait training (RAGT) on the Lokomat (Hocoma AG, Volketswil, Switzerland) for 30 minutes, once a day, 5 times a week, for a total of 20 sessions. All subjects were evaluated for general characteristics, the 10-Meter Walk Test (10MWT), the Lower Extremity Motor Score (LEMS), the Functional Ambulatory Category (FAC), the Walking Index for Spinal Cord Injury version II (WISCI-II), the Berg Balance Scale (BBS), and the Spinal Cord Independence Measure version III (SCIM-III) every 0, and 4 weeks. After all the interventions, subjects were stratified using the 10MWT score at 4 weeks into improved group and non-improved group for statistical analysis. RESULTS: The improved group had younger age and shorter disease duration than the non-improved group. All subjects with the American Spinal Injury Association Impairment Scale level C (AIS-C) tetraplegia belonged to the non-improved group, while most subjects with AIS-C paraplegia, AIS-D tetraplegia, and AIS-D paraplegia belonged to the improved group. The improved group showed greater baseline lower extremity strength, balance, and daily living function than the non-improved group. CONCLUSION: Assessment of SCIM-III, BBS, and trunk control, in addition to LEMS, have potential for predicting the effects of robotic treatment in patients with motor incomplete spinal cord injury.
Gait*
;
Humans
;
Locomotion
;
Lower Extremity
;
Paraplegia
;
Quadriplegia
;
Rehabilitation
;
Robotics
;
Spinal Cord Injuries*
;
Spinal Cord*
;
Spinal Injuries
;
Walking
3.Reduction of Food Intake by Fenofibrate is Associated with Cholecystokinin Release in Long-Evans Tokushima Rats.
Mi Kyoung PARK ; Ying HAN ; Mi Sun KIM ; Eunhui SEO ; Soojeong KANG ; So Young PARK ; Hyeongjong KOH ; Duk Kyu KIM ; Hye Jeong LEE
The Korean Journal of Physiology and Pharmacology 2012;16(3):181-186
Fenofibrate is a selective peroxisome proliferator-activated receptor alpha (PPARalpha) activator and is prescribed to treat hyperlipidemia. The mechanism through which PPARalpha agonists reduce food intake, body weight, and adiposity remains unclear. One explanation for the reduction of food intake is that fenofibrate promotes fatty acid oxidation and increases the production of ketone bodies upon a standard experimental dose of the drug (100~300 mg/kg/day). We observed that low-dose treatment of fenofibrate (30 mg/kg/day), which does not cause significant changes in ketone body synthesis, reduced food intake in Long-Evans Tokushima (LETO) rats. LETO rats are the physiologically normal controls for Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which are obese and cholecystokinin (CCK)-A receptor deficient. We hypothesized that the reduced food intake by fenofibrate-treated LETO rats may be associated with CCK production. To investigate the anorexic effects of fenofibrate in vivo and to determine whether CCK production may be involved, we examined the amount of food intake and CCK production. Fenofibrate-treated OLETF rats did not significantly change their food intake while LETO rats decreased their food intake. Treatment of fenofibrate increased CCK synthesis in the duodenal epithelial cells of both LETO and OLETF rats. The absence of a change in the food intake of OLETF rats, despite the increase in CCK production, may be explained by the absence of CCK-A receptors. Contrary to the OLETF rats, LETO rats, which have normal CCK receptors, presented a decrease in food intake and an increase in CCK production. These results suggest that reduced food intake by fenofibrate treatment may be associated with CCK production.
Adiposity
;
Animals
;
Body Weight
;
Cholecystokinin
;
Diethylpropion
;
Eating
;
Epithelial Cells
;
Fenofibrate
;
Hyperlipidemias
;
Ketone Bodies
;
PPAR alpha
;
Rats
;
Rats, Inbred OLETF
;
Receptor, Cholecystokinin A
;
Receptors, Cholecystokinin
4.A Randomized Controlled Trial for Doing vs. Omitting Intraoperative Frozen Section Biopsy for Resection Margin Status in Selected Patients Undergoing Breast-Conserving Surgery (OFF-MAP Trial)
Tae-Kyung YOO ; Young-Joon KANG ; Joon JEONG ; Jeong-Yoon SONG ; Sun Hee KANG ; Hye Yoon LEE ; Eui Tae KIM ; Onvox YI ; Han-Byoel LEE ; Soojeong CHOI ; Hyung Seok PARK ; Geumhee GWAK ; Jae Il KIM ; Min Kyoon KIM ; Jeeyeon LEE ; Hee Joon KANG ; Byung Joo CHAE
Journal of Breast Cancer 2021;24(6):569-577
Purpose:
Intraoperative frozen section biopsy is used to reduce the margin positive rate and re-excision rate and has been reported to have high diagnostic accuracy. A majority of breast surgeons in the Republic of Korea routinely perform frozen section biopsy to assess margins intraoperatively, despite its long turnaround time and high resource requirements. This study aims to determine whether omitting frozen section biopsy for intraoperative margin evaluation in selected patients is non-inferior to performing frozen section biopsy in terms of resection margin positivity rate.
Methods
This study is a phase III, randomized controlled, parallel-group, multicenter non-inferiority clinical trial. Patients meeting the inclusion criteria and providing written informed consent will be randomized to the “frozen section biopsy” or “frozen section biopsy omission” group after lumpectomy. Patients with clinical stage T1–T3 disease who are diagnosed with invasive breast cancer by core-needle biopsy and plan to undergo breast-conserving surgery will be included in this study. If a daughter nodule, non-mass enhancement, or microcalcification is identified on preoperative imaging, these features must be within 1 cm of the main mass for inclusion in the trial. The target sample size is 646 patients per arm. The primary endpoint will be the resection margin positive rate, and the secondary endpoints include the reoperation rate, operating time, residual cancer after reoperation, residual cancer after re-excision according to the frozen section biopsy result, resection volume, patient quality of life, and cost-effectiveness.Discussion: This is the first randomized clinical trial utilizing frozen section biopsy for intraoperative margin evaluation and aims to determine the non-inferiority of omitting frozen section biopsy in selected patients compared to performing frozen section biopsy.We expect that this trial will help surgeons perform the procedure more efficiently while ensuring patient safety.